These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33148288)

  • 1. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
    Reddy TP; Rosato RR; Li X; Moulder S; Piwnica-Worms H; Chang JC
    Breast Cancer Res; 2020 Nov; 22(1):121. PubMed ID: 33148288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive overview of metaplastic breast cancer: Features and treatments.
    Yan Q; Deng Y; Zhang Q
    Cancer Sci; 2024 Aug; 115(8):2506-2514. PubMed ID: 38735837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
    Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
    Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features of metaplastic breast carcinoma.
    Hasdemir OA; Tokgöz S; Köybaşıoğlu F; Karabacak H; Yücesoy C; İmamoğlu Gİ
    Adv Clin Exp Med; 2018 Apr; 27(4):509-513. PubMed ID: 29558027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metaplastic breast cancer: an all-round multidisciplinary consensus.
    Corso G; Criscitiello C; Nicosia L; Pesapane F; Vicini E; Magnoni F; Sibilio A; Zanzottera C; De Scalzi AM; Mannucci S; Marabelli M; Calvello M; Feroce I; Zagami P; Porta FM; Toesca A; Tarantino P; Nicolò E; Mazzarol G; La Vecchia C; Bonanni B; Leonardi MC; Veronesi P; Fusco N
    Eur J Cancer Prev; 2023 Jul; 32(4):348-363. PubMed ID: 37021548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
    McQuerry JA; Jenkins DF; Yost SE; Zhang Y; Schmolze D; Johnson WE; Yuan Y; Bild AH
    BMC Cancer; 2019 Sep; 19(1):881. PubMed ID: 31488082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
    El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
    Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
    Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
    J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease.
    Takala S; Heikkilä P; Nevanlinna H; Blomqvist C; Mattson J
    Breast J; 2019 May; 25(3):418-424. PubMed ID: 30925636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
    Hu J; Lang R; Zhao W; Jia Y; Tong Z; Shi Y
    Breast Cancer Res Treat; 2023 Jul; 200(1):23-36. PubMed ID: 37160814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
    Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
    Yam C; Abuhadra N; Sun R; Adrada BE; Ding QQ; White JB; Ravenberg EE; Clayborn AR; Valero V; Tripathy D; Damodaran S; Arun BK; Litton JK; Ueno NT; Murthy RK; Lim B; Baez L; Li X; Buzdar AU; Hortobagyi GN; Thompson AM; Mittendorf EA; Rauch GM; Candelaria RP; Huo L; Moulder SL; Chang JT
    Clin Cancer Res; 2022 Jul; 28(13):2878-2889. PubMed ID: 35507014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer.
    Min Kim H; Kim SK; Jung WH; Koo JS
    Tumour Biol; 2015 Feb; 36(2):1207-12. PubMed ID: 25344213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Metaplastic Breast Cancer Versus Triple-Negative Breast Cancer: A Propensity Score Matching Analysis.
    Tan Y; Yang B; Chen Y; Yan X
    World J Surg; 2023 Dec; 47(12):3192-3202. PubMed ID: 37709983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
    Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
    Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
    Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
    J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/β-catenin/mTOR/PI3K signaling.
    Liu L; Yu D; Shi H; Li J; Meng L
    Pharmazie; 2017 Oct; 72(10):599-603. PubMed ID: 29441885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
    Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
    Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.